Crinetics Reports First PALSONIFY Product Revenue of $5.4M in Q4 2025, Strong Launch, Positive EU Opinion, and Pipeline Progress

summarizeSummary

Crinetics Pharmaceuticals announced its Q4 and full-year 2025 financial results, reporting $5.4 million in first product revenue for PALSONIFY, strong launch metrics, a positive EU regulatory opinion, and significant pipeline advancements.

check_boxKey Events

• First Product Revenue Reported

  Crinetics Pharmaceuticals generated $5.4 million in net product revenue from PALSONIFY in Q4 2025, its first quarter of commercial launch, confirming the preliminary results reported earlier.

• Strong PALSONIFY Launch Dynamics

  The U.S. commercial launch of PALSONIFY demonstrated strong early execution with over 200 enrollment forms and prescriptions from more than 125 unique healthcare professionals by the end of December 2025.

• Positive EU Regulatory Opinion

  The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending marketing authorization for PALSONIFY in the EU.

• Pipeline Advancement

  The company initiated three pivotal trials for paltusotine and atumelnant, finalized the protocol for a Phase 2/3 study of atumelnant in Cushing's Syndrome, and advanced a new candidate (CRN09682) into clinical development.

auto_awesomeAnalysis

Crinetics Pharmaceuticals has reported its first product revenue of $5.4 million for PALSONIFY in Q4 2025, marking a significant milestone as the company transitions to a commercial-stage entity. This finalizes the preliminary Q4 revenue exceeding $5 million reported on January 13, 2026. The strong early launch dynamics, including over 200 enrollment forms and prescriptions from over 125 unique healthcare professionals, indicate robust commercial execution. Additionally, the positive CHMP opinion for PALSONIFY in the EU and the advancement of multiple pipeline candidates, including three pivotal trials and a new clinical program, underscore the company's continued R&D momentum. The strong cash position of $1.4 billion following a recent public offering provides substantial runway for ongoing operations and development, supporting the company's strategic goal of building a multi-product endocrinology franchise.